Help improve the lives of women living with metastatic breast cancer – add your voice to our campaign.
Palbociclib (also called Ibrance) is used to treat hormone receptor positive, HER2-negative metastatic breast cancer – the most common subtype of breast cancer. In clinical trials, it has been found to double the length of time before the cancer spreads.
While palbociclib is already available in 52 other countries, it is not yet approved for sale in Australia and is not listed on the PBS. The only way Australian women can get it is by buying it from overseas, at a cost of around $10,000 per month, or participating in a clinical trial.
BCNA member Carolyn has been buying palbociclib for the last nine months. Carolyn has spent more than $100,000 from her superannuation fund but won’t be able to keep paying for it for much longer.
Some of the clinical trials for palbociclib have opened and closed very quickly, meaning some women have missed out. Esma is one of the fortunate women who could access palbociclib through a clinical trial - you can read her experience here.
Palbociclib is currently being considered for sale in Australia by decision makers, but BCNA needs your help. Join our online petition to let the Government know that this is an important new drug for women newly diagnosed with hormone positive, HER2- negative metastatic breast cancer. Women like Carolyn need it to be available in Australia and listed on the PBS now.